Welcome to our dedicated page for United Health Pr news (Ticker: UEEC), a resource for investors and traders seeking the latest updates and insights on United Health Pr stock.
United Health Products reports developments involving its CelluSTAT hemostatic gauze, formerly branded as HemoStyp, a patented Neutralized Regenerated Cellulose hemostatic agent designed to control bleeding. The company develops, manufactures and markets hemostatic products for dental, veterinary and emergency medicine markets and is pursuing access to the human surgical market.
Recurring updates focus on FDA Premarket Approval and Investigational Device Exemption processes, clinical testing, responses to FDA deficiency questions, and product-support work such as sterilization, packaging integrity, biocompatibility and shelf-life testing. Company news also covers financing needs tied to clinical study execution and regulatory application work.
United Health Products, Inc. (OTC: UEEC) has announced the international publication of its patent application for a hydrocolloid format of its hemostatic agent, HemoStyp, under the Patent Cooperation Treaty. This publication allows UHP up to one year to file specific patents in desired countries as it progresses with gel-related R&D. CEO Brian Thom highlighted the potential to expand HemoStyp's market beyond gauze formats, targeting surgical fields like spinal and vascular procedures. The company emphasizes the significance of establishing a global IP portfolio for maximizing technology value.
United Health Products, Inc. (OTC: UEEC) has appointed John Phillips as Vice President of Marketing & Commercial Strategy, effective December 15, 2020. With over 30 years of experience in product commercialization, he will lead UHP’s global commercial strategies for its patented hemostatic agent, HemoStyp. UHP anticipates receiving its FDA PMA, transitioning to commercialization, and enhancing revenue across priority markets. The company aims to leverage Phillips' industry relationships and expertise to improve patient outcomes and reduce care costs.